[ Price : $8.95]
Cubist Pharmaceuticals closes enrollment in its CB-500,929 (ecallantide) Phase 2 program, an investigational therapy for reducing ...[ Price : $8.95]
FDA approves two Tris Pharma NDAs for once-daily clonidine extended-release suspension and tablets to treat hypertension.[ Price : $8.95]
Members of FDAs Cardiovascular and Renal Drugs Advisory Committee say that Novartis Certican appears to be safe and effective in p...[ Price : $8.95]
FDA again says that Somaxons NDA for Silenor to treat insomnia cannot be approved.[ Price : $8.95]
FDA releases its transcripts of last months two-day public hearing on social media.[ Price : $8.95]
Aeterna Zentaris says that its benign prostatic hyperplasia drug filed to meet its endpoint in a 39-site European Phase 3 trial.[ Price : $8.95]
Federal Register Notice: FDA releases a draft guidance on assay development for immunogenicity testing of therapeutic proteins.[ Price : $8.95]
Former FDA deputy commissioner Mary Pendergast warns that CDER is making stealth comparative effectiveness decisions on standard N...